Montefiore Joined Clinical Trial for DCIS Breast Condition
A new study tests if adults with early-stage breast findings can safely avoid immediate surgery.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Do you trust medical approaches that prioritize monitoring over immediate surgery for early-stage cancer conditions?
The Montefiore Einstein Comprehensive Cancer Center has joined the RECAST clinical trial to investigate treatment alternatives for ductal carcinoma in situ (DCIS). This trial explores whether patients can safely manage the condition through medication and monitoring rather than immediate surgery.
Why it matters
Researchers are working to identify which DCIS cases can be safely managed without the risks associated with surgery. This study aims to define new standards for care by potentially sparing patients from invasive procedures when active monitoring is appropriate.
The RECAST trial is a multi-site study involving 400 patients across 20 locations assessing four distinct medical treatment approaches for estrogen receptor-positive DCIS. These findings are preliminary, as the study is ongoing and aims to evaluate safety before any clinical practice shifts.
The players
Montefiore Einstein Comprehensive Cancer Center
A medical institution and cancer care provider that previously participated in the COMET trial regarding DCIS treatment.
I-SPY research network
A collaborative clinical research consortium that utilizes advanced trial designs to accelerate the evaluation of breast cancer therapies.
The details
DCIS is a stage zero breast condition where atypical cells are present within the milk ducts. Participants in this trial undergo a specialized MRI to assess the condition before being randomly assigned to one of four medication regimens. Instead of immediate surgery, patients receive ongoing care through follow-up MRIs to detect any disease progression. If scans indicate the condition is advancing, patients then proceed to surgical intervention.
Timeline
October 2026: The Montefiore Einstein Comprehensive Cancer Center site began participating in the clinical trial.
Three months: Patients receive their first follow-up MRI.
Six months: Patients receive a subsequent follow-up MRI.
Two to three years: The expected total duration of the ongoing clinical trial.
Health Landscape
The RECAST trial builds upon previous efforts like the COMET trial to move beyond a one-size-fits-all surgical approach for DCIS. It represents a shift in oncology research toward identifying high-precision, non-surgical management options for early-stage breast conditions.
If you have received a DCIS diagnosis, it is worth discussing the potential for non-surgical monitoring with your oncologist. This trial reinforces the importance of using imaging, such as specialized MRIs, to track the progression of early-stage findings over time.
The takeaway
DCIS is a stage zero finding with a 100% prognosis for cure, making the search for less invasive treatment paths a clinical priority. Always discuss the risks and benefits of surgery versus surveillance with your doctor to determine which approach aligns with your specific health profile.
Further reading
For more information on the latest developments in breast health, visit our Cancer section.
Source note: This article includes information reported by Bronx Times.
Live Poll
Do you trust medical approaches that prioritize monitoring over immediate surgery for early-stage cancer conditions?
